T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma_新闻中心_T-MAXIMUM Biotech

T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

Author: Release time: 2026/1/5 11:28:40

Previous:T-MAXIMUM Biotech 's MT027 has been granted orphan drug designation by the US FDA

Next:Nothing